PITOLISANT

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
PITOLISANT
Generic name
PITOLISANT
Manufacturer
Lupin Pharmaceuticals, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
6fb94d86-5154-4b69-8470-d1145d426312
SPL ID
e46eef01-594a-49ca-a453-0b680e4ee730
Version
10
Effective date
2026-10-16
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:36:01
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS QT Interval Prolongation: Increases in QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval. Monitor patients with hepatic or renal impairment for increased QTc ( 5.1 ) 5.1 QT Interval Prolongation Pitolisant tablets prolong the QT interval. The use of pitolisant tablets should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. Pitolisant tablets should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval [see Clinical Pharmacology ( 12.2 )]. The risk of QT prolongation may be greater in patients with higher concentrations of pitolisant (e.g., patients with hepatic or renal impairment). Monitor patients with hepatic or renal impairment for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment [see Dosage and Administration ( 2.4 , 2.5 )]. Pitolisant tablets are contraindicated in patients with severe hepatic impairment [see Contraindications ( 4 )]. Pitolisant tablets are not recommended in patients with end-stage renal disease (ESRD) [see Dosage and Administration ( 2.5 ), Use in Specific Populations ( 8.7 ), Clinical Pharmacology ( 12.3 )].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: QT Interval Prolongation [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (≥5%and at least twice placebo) in adults: insomnia, nausea, and anxiety ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients with Narcolepsy In clinical trials for narcolepsy, 172 adult patients were treated with pitolisant tablets in placebo-controlled trials for up to 8 weeks and in open-label extension trials for up to 5 years. In trials in which pitolisant tablets was directly compared to placebo, 6 of the 152 patients (3.9 %) who received pitolisant tablets and 4 of the 114 patients (3.5 %) who received placebo discontinued because of an adverse reaction. Most Common Adverse Reactions In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (occurring in ≥5 % of patients and at least twice the rate of placebo) with the use of pitolisant tablets were insomnia (6 %), nausea (6 %), and anxiety (5 %). Table 1 presents the adverse reactions that occurred at a rate of ≥2 % in patients treated with pitolisant tablets and more frequently than in patients treated with placebo in the placebo-controlled clinical trials in narcolepsy. Table 1: Adverse Reactions that Occurred in ≥2 % of Pitolisant Tablets-Treated Patients and More Frequently than in Placebo-Treated Patients in Three Placebo-Controlled Narcolepsy Studies * The following terms were combined: Abdominal pain includes: abdominal discomfort; abdominal pain; abdominal pain upper Anxiety includes: anxiety; nervousness; stress; stress at work Hallucinations includes: hallucination; hallucination visual; hypnagogic hallucination Headache includes: cluster headache; headache; migraine; premenstrual headache; tension headache Heart rate increased includes: heart rate increased; sinus tachycardia; tachycardia Insomnia includes: initial insomnia; insomnia; middle insomnia; poor quality sleep Musculoskeletal pain includes: arthralgia; back pain; carpal tunnel syndrome; limb discomfort; musculoskeletal pain; myalgia; neck pain; osteoarthritis; pain in extremity; sciatica Rash includes: eczema; erythema migrans; rash; urticaria Sleep disturbance includes: dyssomnia; sleep disorder; sleep paralysis; sleep talking Upper respiratory tract infection includes: pharyngitis; rhinitis; sinusitis; upper respiratory tract infection; upper respiratory tract inflammation; viral upper respiratory tract infection Adverse Reaction Pitolisant Tablets (n=152) % Placebo (n=114) % Headache* 18 15 Insomnia* 6 2 Nausea 6 3 Upper Respiratory Tract Infection* 5 3 Musculoskeletal Pain* 5 3 Anxiety* 5 1 Heart Rate Increased* 3 0 Hallucinations* 3 0 Irritability 3 2 Abdominal Pain* 3 1 Sleep Disturbance* 3 2 Decreased Appetite 3 0 Cataplexy 2 1 Dry Mouth 2 1 Rash* 2 1 Pediatric use information is approved for Harmony Biosciences Management Inc.'s WAKIX (pitolisant) tablets. However, due to Harmony Biosciences Management Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of pitolisant tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: General disorders and administration site conditions: Fatigue Immune system disorders: hypersensitivity (anaphylaxis) Investigations: weight increased Nervous system disorders: dizziness , Epilepsy Psychiatric disorders: abnormal behavior, abnormal dreams, anhedonia, bipolar disorder, depression, depressed mood, nightmare, sleep disorder, suicide attempt, suicidal ideation Skin and subcutaneous tissue disorders: Pruritus

adverse reactions table

<table ID="ID43" width="0" styleCode="Noautorules"> <caption> Table 1: Adverse Reactions that Occurred in &#x2265;2 % of Pitolisant Tablets-Treated Patients and More Frequently than in Placebo-Treated Patients in Three Placebo-Controlled Narcolepsy Studies </caption> <col width="274"/> <col width="170"/> <col width="180"/> <tfoot> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote">* The following terms were combined:</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Abdominal pain includes: </content> abdominal discomfort; abdominal pain; abdominal pain upper</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Anxiety includes: </content> anxiety; nervousness; stress; stress at work</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Hallucinations includes: </content> hallucination; hallucination visual; hypnagogic hallucination</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Headache includes: </content> cluster headache; headache; migraine; premenstrual headache; tension headache</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Heart rate increased includes: </content> heart rate increased; sinus tachycardia; tachycardia</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Insomnia includes: </content> initial insomnia; insomnia; middle insomnia; poor quality sleep</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Musculoskeletal pain includes: </content> arthralgia; back pain; carpal tunnel syndrome; limb discomfort; musculoskeletal pain; myalgia; neck pain; osteoarthritis; pain in extremity; sciatica</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Rash includes: </content> eczema; erythema migrans; rash; urticaria</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Sleep disturbance includes: </content> dyssomnia; sleep disorder; sleep paralysis; sleep talking</paragraph> </td> </tr> <tr> <td align="left" colspan="3"> <paragraph styleCode="Footnote"> <content styleCode="bold"> Upper respiratory tract infection includes: </content> pharyngitis; rhinitis; sinusitis; upper respiratory tract infection; upper respiratory tract inflammation; viral upper respiratory tract infection</paragraph> </td> </tr> </tfoot> <tbody> <tr> <td styleCode="Lrule Toprule Botrule Rrule" align="center"> <content styleCode="bold"> Adverse Reaction</content> </td> <td styleCode=" Toprule Botrule Rrule" align="center"> <content styleCode="bold"> Pitolisant Tablets</content> <content styleCode="bold"> (n=152)</content> <content styleCode="bold"> %</content> </td> <td styleCode=" Toprule Botrule Rrule" align="center"> <content styleCode="bold"> Placebo</content> <content styleCode="bold"> (n=114)</content> <content styleCode="bold"> %</content> </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Headache* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 18 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 15 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Insomnia* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Nausea </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Upper Respiratory Tract Infection* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Musculoskeletal Pain* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Anxiety* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Heart Rate Increased* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Hallucinations* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Irritability </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Sleep Disturbance* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Cataplexy </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Dry Mouth </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td> </tr> <tr> <td styleCode="Lrule Botrule Rrule" align="left"> Rash* </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td> <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.